Abstract:Experimental models shows that bioenergetic homeostasis changes with increasing age based on apolipoprotein E ( APOE ) gene. However, such link with dementia remains unclear in population. We used H[1][1]-NMR metabolome in blood from 118,021 random-selected participants in UK Biobank (n=118,021 individuals), and identified 56 metabolites associated with the risk of dementia. In the participants without developing dementia during follow-up, 82% (46/56) metabolites are also associated with reaction time, and dementia shares metabolite signatures with total brain volume. We found that incident Alzheimer’s disease (AD) is associated with energy metabolism-related metabolites, i.e, β-hydroxybutyrate, acetone, and valine, whose concentrations in blood are influenced by age and APOE genotype. Valine shows a declined trajectories after a plateau at age around 60 years which is in parallel with body mass index. Moreover, we found associations of AD with valine and β-hydroxybutyrate in brain tissue are different as their associations in the periphery, which implies the key role of transports in regulating the energy metabolism of AD. Our study provides strong evidence in population level that the onset of AD in APOE4 carriers is regulated by the impaired energy balance in the brain. ### Competing Interest Statement Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix. All other authors declare no conflicts of interest. ### Funding Statement In this study, metabolomics data is provided by the Alzheimer,s Disease Metabolomics Consortium (ADMC) and funded wholly or in part by the following grants and supplements thereto: NIA R01AG046171, RF1AG051550, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744 and FNIH: #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. As such, the investigators within the ADMC, not listed specifically in this publication,s author,s list, provided data along with its pre-processing and prepared it for analysis, but did not participate in analysis or writing of this manuscript. A complete listing of ADMC investigators can be found at: <https://sites.duke.edu/adnimetab/team/>. ROSMAP data were provided by the Rush Alzheimer,s Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at [www.radc.rush.edu][2]. Study data were provided through NIA grant 3R01AG046171-02S2 awarded to Rima Kaddurah-Daouk at Duke University, based on specimens provided by the Rush Alzheimer,s Disease Center, Rush University Medical Center, Chicago, where data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The ethics committee in North West Multi-centre Research Ethics Committee, the Patient Information Advisory Group, and the Community Health Index Advisory Group gave ethical approval for this work related to UK Biobank. The corresponding ethical committees of our collaborator's institutions as well as the Institutional Review Board (IRB) of Columbia University Medical Center (protocol AAAR4962) gave ethical approval for this work related to ROS/MAP. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes UK Biobank data are available through a procedure described at [http://www.ukbiobank.ac.uk/using-the-resource/][3]. Data from ROSMAP are available through the Rush AD Center Resource Sharing Hub (<https://www.radc.rush.edu>). All the summary statistics are available in the supplementary tables. <http://www.ukbiobank.ac.uk/using-the-resource/> <https://www.radc.rush.edu> [1]: #ref-1 [2]: https://www.radc.rush.edu [3]: https://www.ukbiobank.ac.uk/using-the-resource/

The ROSMAP project: aging and neurodegenerative diseases through omic sciences

A multi-omic atlas of the human frontal cortex for aging and Alzheimer’s disease research

Network analysis of brain and bone tissue transcripts reveals shared molecular mechanisms underlying Alzheimer's Disease and related dementias (ADRD) and Osteoporosis

Plasticity of Human Microglia and Brain Perivascular Macrophages in Aging and Alzheimer’s Disease

A public resource of single cell transcriptomes and multiscale networks from persons with and without Alzheimer’s disease

Integrated multimodal cell atlas of Alzheimer's disease

Longitudinal analysis of UK Biobank participants suggests age and APOE-dependent alterations of energy metabolism in development of dementia

Integrated multimodal cell atlas of Alzheimer’s disease

Alzheimer DataLENS: An Open Data Analytics Portal for Alzheimer's Disease Research

Bridging the Gap: Multi-Omics Profiling of Brain Tissue in Alzheimer's Disease and Older Controls in Multi-Ethnic Populations

Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort

Multi-Omic Characterization of Brain Changes in the Vascular Endothelial Growth Factor Family during Aging and Alzheimer's Disease

MU-BRAIN: MUltiethnic Brain Rna-seq for Alzheimer INitiative

OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease

Multi-cellular Communities Are Perturbed in the Aging Human Brain and Alzheimer’s Disease

Multicellular communities are perturbed in the aging human brain and Alzheimer's disease

A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease

Multivariate investigation of aging in mouse models expressing the Alzheimer's protective APOE2 allele: integrating cognitive metrics, brain imaging, and blood transcriptomics

ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases

Proteomic Signature and Mrna Expression in Hippocampus of SAMP8 and SAMR1 Mice During Aging